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Abstract
Background: Generation of functional CD4+CD8-CD25+ regulatory T cells (Treg) in the murine
thymus depends on FoxP3. Removal of the thymus from neonatal mice has been shown to result
in a multiple organ autoimmune disease phenotype that can be prevented by introducing the
FoxP3+ Treg population to the animal. It has therefore, been proposed that functional FoxP3+ Treg
cells are not made in the neonatal thymus; however, it remains unclear when and where functional
FoxP3+CD4+CD8-CD25+ thymocytes are generated in postnatal thymus.
Results: We report that neither FoxP3 mRNA nor protein is expressed in CD4+CD8-CD25+, or
CD4+CD8-CD25- thymocytes until 3–4 days post birth, despite the presence of mature CD4+CD8-
CD25+/- thymocytes in the thymus by 1–2 days after birth. FoxP3-CD4+CD8-CD25+ thymocytes
from day 2 newborn mice show no Treg activity. Interestingly, we are able to detect low numbers
of FoxP3+ thymocytes dispersed throughout the medullary region of the thymus as early as 3–4
days post birth. Expression of FoxP3 is induced in embryonic day 17 fetal thymus organ culture
(FTOC) after 4–6 days of in vitro culture. Treatment of FTOCs with thymic stromal derived
lymphopoietin (TSLP) enhanced expression of FoxP3, and blocking the TSLP receptor reduces
FoxP3 expression in FTOC. Furthermore, TSLP stimulates FoxP3 expression in purified
CD4+CD8- thymocytes, but not in CD4+CD8+, CD4-CD8+ and CD4-CD8- thymocytes.
Conclusion: Expression of FoxP3 or Treg maturation is ontogenically distinct and kinetically
delayed from the generation of CD4+CD8-CD25+  or CD4+CD8-CD25-  thymocytes in the
postnatal thymus. TSLP produced from medullary thymic epithelia cells (mTEC) contributes to the
expression of FoxP3 and the maturation of natural regulatory T cells. Overall, these results suggest
that the development of Treg cells requires paracrine signaling during late stages of thymocyte
maturation that is distinct from signaling during positive or negative selection.
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Background
It has been well-documented that the thymus plays a cen-
tral role in deleting self-reactive T cells via negative selec-
tion. In addition, T cells with suppressive activity are
generated in the thymus to regulate peripheral immunity
[1,2]. Removal of the thymus from 3 day old neonatal
mice leads to multiple organ autoimmune disease in
some strains of mice [3-6]; however, removal of the thy-
mus from mice 7 days old or older causes little or no
autoimmunity. These observations have led to the pro-
posal that T cells with suppressive activity in the thymus
are either not generated in or fail to emigrate from the thy-
mus in neonatal mice. Indeed, transfer of a subset of adult
CD4+CD8-CD25+  thymocytes (natural regulatory T or
Treg cells) into day 3 thymectomized mice prevents
autoimmune disease [7-9].
Natural CD4+CD25+ regulatory T cells are present in the
thymus and peripheral lymphoid organs [9,10]. Although
studies have clearly shown that Treg cells are generated in
the thymus, these cells can also be derived from mature T
cells in the peripheral organs [11,12]. While the molecular
mechanisms of Treg lineage development are poorly
understood, recent genetic studies in both mice and
humans have identified Scurfin or FoxP3, a forkhead fam-
ily transcription factor, as a master determinant of Treg
development and function [13-18]. Mice carrying muta-
tions in the FoxP3 gene (scurfy mice) exhibit lymphopro-
liferative diseases and autoimmune phenotypes. These
mice have been found to lack functional Treg cells. Simi-
larly, human patients with mutations in the FoxP3 gene
develop a multiple organ autoimmune disorder known as
IPEX which is consistent with a lack of Treg cells. Finally,
ectopic expression of FoxP3 in naïve CD4+CD25- T cells
causes them to convert to Treg cells [15,17], and targeted
inactivation of FoxP3 in mice leads to loss of Treg devel-
opment [16,18]. The preferential expression of FoxP3 in
Treg cells and its deterministic activity in Treg lineage
development make it the best marker of natural Treg cells,
although the regulation of its expression and the mecha-
nisms of its function in Treg are not yet elucidated.
According to the affinity/avidity model, CD4+CD8+ DP
thymocytes in the cortex or the cortical-medullary junc-
tions (CMJ) that interact with self-MHC at low levels are
rescued from death, thus positively selected. Alternatively,
thymocytes are induced to die by negative selection if the
interactions between thymocytes and thymic epithelial
cells (TEC) or antigen presenting cells (APC) result in sig-
naling above a certain threshold. These types of high-
affinity interactions with self antigen are most efficiently
mediated by APC, and usually occur at the CMJ. It has
been proposed that induction of FoxP3 and maturation of
the Treg lineage represent a separate lineage in the thymus
due to selection signals that fall between those of positive
and negative selection [19-22]. This hypothesis, however,
has not been clearly verified. Interestingly,
FoxP3+CD4+CD25+ T cells have been induced in periph-
eral organs by prolonged exposure to their cognate anti-
gens, suggesting that natural Treg-like cells can also be
generated in a thymus-independent fashion [12,23].
We have investigated the kinetics of FoxP3 expression and
generation of CD4+CD8-CD25+ thymocytes in thymus
organs of mice at various ages after birth. We demonstrate
that neither FoxP3 mRNA nor protein is significantly
expressed in CD4+CD8-CD25+, CD4+CD8-CD25- or other
thymocytes until 3–4 days post birth, despite the presence
of CD4+CD8-CD25+ thymocytes in the thymus of 1–2 day
old neonatal mice. FoxP3 expression is induced at 3–4
days after birth and detected in both CD4+CD8-CD25+
and CD4+CD8-CD25- thymocytes. As expected, FoxP3-
CD4+CD8-CD25+ thymocytes from day 2 newborn mice
proliferate in vitro and show no suppressive Treg activity.
While an increasing percentage of CD4+CD8-CD25+ thy-
mocytes expresses FoxP3 from day 3 (21%) to day 8
(59%), a small population (<1%) of CD4+CD8-CD25-
thymocytes also expresses FoxP3. Almost all FoxP3+ thy-
mocytes are detected in the medullary region of the thy-
mus even in 3–4 day old mice. Expression of FoxP3 is
induced in embryonic day 17 fetal thymus organ culture
(FTOC) 4–6 days after culture in vitro. Treatment of FTOC
with thymic stromal derived lymphopoietin (TSLP)
Table 1: FoxP3+CD4+CD25+ thymocytes in neonatal mice a
# Cells (103) day 1 day2 day 3 day 4 day 5 day 6 day 8 Adult
Total 
Thymocyte
1,005 b +/-177 3,390 +/-410 6,210 +/-127 9,410 +/-
2,107
32,600 +/-
18,668
31,000 +/-
12,021
57,700 +/-
2,263
75,900 +/-
12,304
CD4+CD8- 13 +/-1.9 117 +/-36.4 457 +/-44.5 350 +/-16.2 828 +/-526 732 +/-361 1,738 +/-256 5,606 +/-
1,751
CD4+CD25+
CD8-
0.1 (.82%)C +/
-0.02
0.9 (.86%) +/-
0.6
3.1 (.86%) +/-
0.3
2.6 (.92%) +/-
0.2
3.7 (.76%) +/-
2.2
4.5 (.98%) +/-
1.9
18.1 (.86%) +/
-0.3
91.1 (2.2%) +/
-27
Foxp3+CD4+
CD25+CD8-
0 0 0.8 (21%)d +/-
0.1
0.9 (37%) +/-
0.1
1.6 (43%) +/-
0.9
1.9 (43%) +/-
0.7
10.8 (59%) +/-
0.1
64.5 (71%) +/-
17.9
a Total thymocytes from day 1–8 newborn or adult mice were stained with CD4, CD8, CD25 and anti-FoxP3 antibody and analyzed by FACS. Data 
is a summary of three independent analyses. b: Average cell number +/- standard deviations (SD). c: % CD25+ of CD4+CD8- thymocytes. d: % FoxP3+ 
of CD4+CD25+CD8- thymocytes.BMC Immunology 2006, 7:6 http://www.biomedcentral.com/1471-2172/7/6
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enhances expression of FoxP3. This expression correlates
with increased maturation of FoxP3+CD4+CD25+ thymo-
cytes. Blocking the TSLP receptor significantly reduces
FoxP3 expression in FTOC. TSLP stimulates FoxP3 expres-
sion in purified CD4+CD8-  thymocytes, but not in
CD4+CD8+, CD4-CD8+ or CD4-CD8- thymocytes.
Results
Delayed expression of FoxP3 in CD4+CD25+ thymocytes 
from thymus organs of neonatal mice
We investigated the ontogenic development of Treg cells
in thymus organs from newborn mice. Comparable per-
centages of CD4+CD8- thymocytes with Treg phenotypes
(CD4+CD8-CD25+) are detected in day 1–8 neonatal thy-
mus organs (Fig. 1A and Table 1). When measured by real-
time PCR in thymocytes from neonatal mice, FoxP3
mRNA expression was not detected in thymocytes from 1
and 2 day old mice. Significant levels of FoxP3 expression
were detected in thymocytes from the thymus of mice 3
days or older (Fig. 1B and data not shown). These data
show that though CD4+CD25+ thymocytes are present in
1–2 day old mice, FoxP3 is not expressed until 3 days after
birth.
To analyze if and when the FoxP3 protein is expressed in
new born thymocytes, we generated an anti-FoxP3 anti-
body. Using 293T cells transfected with mouse FoxP3, we
showed that this antibody could be used to detect FoxP3
by Western, immunofluorescence staining and FACS anal-
ysis (Fig. 2A). Anti-FoxP3 antibodies specifically stained
intracellular FoxP3 in CD4+CD25+ Treg cells isolated from
wild type, but not scurfy, mice by FACS (Fig. 2A, right).
Using the anti-FoxP3 antibody, we showed that the FoxP3
protein was not detected in the CD4+CD8-CD25+ thymo-
cytes from 1 and 2 day old neonatal mice as determined
by FACS (Fig. 2B). Significant levels of FoxP3 were first
detected in CD4+CD25+ and CD4+CD25- cells from the 3
day old thymus (21% FoxP3+ cells in CD4+CD8-CD25+
thymocytes), reached high levels at 6–8 days (41 % in day
6 and 59 % in day 8), and were further elevated and main-
tained in the adult thymus (70 % FoxP3+  cells in
CD4+CD8-CD25+ thymocytes) (Fig. 2B and Table 1). Con-
sistent with recent reports in the adult thymus [24,25], a
small population (<1%) of CD4+CD8-CD25- thymocytes
also expressed FoxP3 (Fig. 2B, 4C and data not shown).
Therefore, expression of FoxP3 seems to lag behind the
generation of CD4+CD8-CD25+  thymocytes, indicating
that maturation of FoxP3+ Treg thymocytes are delayed
relative to mature single positive thymocytes (CD4+CD8-
CD25+ or CD4+CD8-CD25-). This delay in maturation
and FoxP3 expression in the newborn thymus may help to
explain the preferential lack of Treg cells in day 3 thymec-
tomized mice.
CD4+CD8-CD25+ thymocytes from day 2 newborn mice 
are not functional Treg cells
To investigate if the CD4+CD8-CD25+ thymocytes in day
2 newborn mice are functional Treg cells, we sorted this
population and analyzed their proliferation and suppres-
sive capacity in vitro. As shown in Fig. 3, adult Treg cells
expressing FoxP3 showed no proliferation and efficiently
suppressed responder T cells. In contrast, CD4+CD8-
Distinct development of SP4 (CD4+CD8-CD25+/-) cells and FoxP3 gene expression in new born thymus organs Figure 1
Distinct development of SP4 (CD4+CD8-CD25+/-) cells and FoxP3 gene expression in new born thymus organs. 
A: Comparable levels of CD4+CD8-CD25+ thymocytes are present in day 1–8 neonatal and adult thymus. Neonatal thymus 
organs were analyzed for CD4, CD8 and CD25 by FACS. Relative percentages of CD4+ thymocytes and CD4+CD8-CD25+ 
thymocytes are indicated. Shown are neonatal mice from a representative litter of at least three independent experiments. B: 
FoxP3 mRNA is not expressed in neonatal thymocytes until 3 days after birth. Total cells from the newborn thymus were har-
vested at indicated times after birth and analyzed for relative expression of FoxP3 (FoxP3/18S) by real-time PCR. SD is derived 
from duplicate samples and shown as error bars. At least 4 litters of newborn mice were analyzed with similar results.
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CD25+ thymocytes from day 2 newborn mice proliferated
in response to TCR stimulation in vitro and did not sup-
press proliferation of CD4+CD25- responder T cells, indi-
cating that they were not functional Treg cells.
Localization of FoxP3+ Treg cells in the thymus of neonatal 
and adult mice
To determine the localization and phenotype of FoxP3+
Treg cells in the neonatal thymus, we performed immuno-
histochemical and immunofluorescence staining. As
shown in Figure 4A, FoxP3+ cells were not detected in the
thymus of 1–2 day old neonatal mice. Low numbers of
FoxP3+ cells were first detectable in the thymus of 3 day
old mice. The number of FoxP3+ cells increased signifi-
cantly in the 4–5 day old thymus and reached adult levels
in the 6 day old thymus (Fig. 4A and 4B). Interestingly,
almost all FoxP3+ cells are sparsely localized in the med-
ullar region of the thymus (Fig. 4A and 4C). This observa-
tion holds true even in 3–4 day old mice, suggesting the
importance of the thymic medulla in providing the para-
crine factors to induce FoxP3 expression and Treg matura-
tion.
Enhanced expression of FoxP3 by TSLP in fetal thymus 
organ culture
Thymic stromal derived lymphopoietin (TSLP) is a type I
cytokine predominantly produced by thymic medullary
epithelial cells and has been recently shown to modulate
human DC and T cell responses [26-28], and to promote
proliferation of CD4+ T cells in mice [29]. Because of this
finding and its expression in the medulla, we decided to
test the hypothesis that TSLP is also involved in the induc-
tion of Treg development in mouse thymus organs. We
investigated the kinetics of FoxP3 expression in thymus
Delayed FoxP3 expression in CD4+CD8-CD25+/- cells in neonatal thymus Figure 2
Delayed FoxP3 expression in CD4+CD8-CD25+/- cells in neonatal thymus. A: Generation and characterization of the 
anti-FoxP3 antibody.293T cells were transfected with either vector or pHSPG-mFoxp3. FoxP3 was specifically detected by 
Western blot with the anti-FoxP3 antibody (top left), immunofluorescence (IF) staining (lower left), by FACS analysis (middle). 
The anti-FoxP3 antibody specifically stained intracellular FoxP3 in CD4+CD8-CD25+ Treg cells from wild type, but not scurfy, 
mice (right). B: Expression of FoxP3 protein is not detected in CD4+CD8-CD25+ thymocytes until 3 days after birth. Percent-
ages of CD4+CD8-CD25+ and CD4+CD8-CD25- thymocytes (gate on the CD4+CD8- population from Fig. 1A) that expressed 
FoxP3 are shown, with the control IgG as background.
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organs from day 17 embryos cultured in vitro (FTOC).
Expression of FoxP3 was not detectable in day 0 or day 2
FTOC, but was detected at significant levels after 4–6 days
in culture (Fig. 5A). We therefore used the E17 FTOC
model to investigate paracrine signals that contribute to
the expression of FoxP3 in the thymus. When tested in the
FTOC model, TSLP enhanced the expression of FoxP3 in
the thymus (Fig. 5B). While the total number of thymo-
cytes was not significantly changed, TSLP treatment did
significantly enhance maturation of CD4+ and CD8+ sin-
gle positive thymocytes. In addition, both the relative per-
centage and total number of CD4+CD25+  thymocytes
were enhanced (Fig. 5D). These observations indicate that
exogenous TSLP promotes maturation of thymocytes,
including the CD4+CD8-CD25+FoxP3+ natural Treg cells
in the thymus.
To demonstrate that endogenous TSLP-mediated signal-
ing is required in the thymus for FoxP3 expression, we
used an antibody that blocks the TSLP receptor (TSLPR) in
the FTOC model. Blocking the TSLPR with this antibody
inhibited FoxP3 expression, whereas a control antibody
showed no effect (Fig. 5C and data not shown). This
experiment suggests that TSLP-mediated signaling is
involved in the expression of FoxP3 and maturation of
Treg thymocytes in the thymus. Similar fractions of
FoxP3+CD4+CD25+ thymocytes were, however, found in
TSLPR-null and age-matched wild type mice (data not
shown). TSLP, therefore, contributes to, but is not abso-
lutely required for, the maturation of FoxP3+CD4+CD25+
Treg cells in the murine thymus.
TSLP enhances FoxP3 expression in purified CD4+CD8- 
thymocytes in vitro
To investigate whether TSLP interacts directly with thymo-
cytes to induce FoxP3 expression or indirectly via interac-
tions with other cell types such as DCs in the thymus as
reported in humans [26-28], we isolated thymocytes from
2 day old mice and treated them with TSLP in vitro for 2
days. As seen above in FTOC, TSLP promoted the matura-
tion of thymocytes including the CD4+CD8-CD25+FoxP3+
natural Treg thymocytes (Fig. 6A, 6B and 6C). In the
absence of TSLP, freshly isolated thymocytes from 2 days
old thymus did not express detectable levels of FoxP3 after
2 days in culture. TSLP induced FoxP3 expression at both
protein and mRNA levels in cultured thymocytes (Fig. 6B
and 6D). Using TSLP receptor mutant thymocytes, we
couldn't detect any enhancement of FoxP3 expression by
TSLP, proving that TSLP was indeed working through the
TSLP receptor in this system (Fig. 8). The data suggest that,
in contrast to human TSLP which mediates DC matura-
tion and indirectly induces Treg activity in the human thy-
mus, mouse TSLP can interact directly with mouse
thymocytes to promote maturation of FoxP3+CD4+CD25+
thymocytes and to enhance FoxP3 gene expression.
To test which thymocyte subpopulations directly respond
to TSLP, we purified CD4+CD8+ (DP), CD4-CD8- (DN),
CD4+CD8-  (SP4) or CD4-CD8+  (SP8) thymocytes and
treated them with TSLP in vitro for two days. TSLP
enhanced expression of FoxP3 in SP4 thymocytes, but not
in DP, DN or SP8 thymocytes (Fig. 7A). We further subdi-
vided the SP4 and SP8 thymocyte populations based on
their expression of CD25. TSLP enhanced FoxP3 expres-
sion by 10-fold in CD4+CD25- thymocytes, and about 2-
fold in CD4+CD25+ thymocytes (Fig. 7B). In contrast, nei-
ther CD25+  nor CD25-  SP8 thymocytes responded to
TSLP. We also investigated if TSLP affects the proliferation
or survival of thymocytes during the two day culture in
vitro. Our results showed that TSLP treatment affected nei-
ther the proliferation nor the survival of CD4+CD25- or
CD4+CD25+ thymocytes (Fig. 9A and 9B). Together our
data suggest that interaction of TSLP with its receptor can
promote FoxP3 expression and CD4+CD25+FoxP3+ Treg
development in the thymus, at least partly via direct inter-
action with CD4+ SP thymocytes.
Discussion
We report here that, although mature single positive thy-
mocytes including CD4+CD25+  thymocytes can be
detected in day 1–2 neonatal mice, the FoxP3 gene is not
expressed in the thymus until 3–4 days after birth and the
expression dose not approach adult levels until after 6–8
days. FoxP3 expression was detected in both CD4+CD8-
CD4+CD8-25+ thymocytes from day 2 thymus are not func- tional Treg cells Figure 3
CD4+ CD8- 25+ thymocytes from day 2 thymus are 
not functional Treg cells. CD4+CD8-CD25+ thymocytes 
from day 2 newborn thymus or mature Treg cells from adult 
mice were purified and activated alone or mixed at 1:2 ratio 
with fixed number of CD4+CD25- responder T cells. Prolif-
eration was determined after 3 days of culture using 3H-thy-
midine incorporation. Error bars indicate SD of triplicate 
samples.
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CD25+  and CD4+CD8-CD25-  thymocytes. As expected,
FoxP3-CD4+CD8-CD25+ thymocytes from day 2 newborn
mice show no Treg activity. Almost all FoxP3+ thymocytes
are detected in the medullary region of the thymus. In
addition, we have demonstrated that TSLP enhances mat-
uration of CD4+CD8-CD25+ thymocytes as well as FoxP3
expression, and that blocking endogenous TSLPR in the
thymus inhibits FoxP3 expression. Furthermore, TSLP
interacts directly with CD4+ SP thymocytes to affect FoxP3
expression and Treg development.
Our findings agree with a recent report showing that lower
levels of FoxP3 mRNA were detected in CD4+CD25+ T
cells from 3 day old newborn mice [30]. This report, how-
ever, failed to clarify whether FoxP3 is expressed in 1–2
day old mice, and if all Treg cells from 3 day old mice
express lower levels of FoxP3 mRNA or if a smaller frac-
tion of these cells expresses the same level of FoxP3 mRNA
as CD4+CD25+ Treg cells from adult mice. We have dem-
onstrated here that FoxP3 expression is not detectable in
Treg-like cells from 1–2 day old mice, and that a smaller
fraction of day 3 neonatal CD4+CD25+  thymocytes
expresses the FoxP3 protein at levels comparable to
mature adult Treg cells.
As detected by immuno-staining of thymus tissues, both
CD4+CD25+FoxP3+  and CD4+CD25-FoxP3+  cells were
detected in the thymus (Fig. 3). FoxP3+ thymocytes are
induced in the 3–4 day old thymus, with a medullary dis-
tribution similar to that seen in the adult thymus. This is
consistent with a recent report using the FoxP3-GFP
knock-in mouse. In this model, expression of FoxP3 is
detected by GFP [24,31]. Similar to our finding using anti-
FoxP3 staining, the FoxP3-GFP+ thymocytes start to be
detectable in the medulla of the 3–4 day old thymus.
These results suggest that CD4+CD25+ thymocytes need
paracrine signals provided by cells in the medullary region
to become fully mature FoxP3+ Treg thymocytes. As posi-
tive selection and negative selection of thymocytes occurs
predominantly in the cortex and the CMJ, we would
expect a preferential localization of emerging FoxP3+ thy-
mocytes in the cortex/CMJ if commitment to natural Treg
and FoxP3 induction is closely related to the TCR-medi-
ated positive/negative selection. The dispersed medullary
distribution of FoxP3+ thymocytes in 3–4 day old thymus
organs supports the idea that induction of FoxP3 expres-
sion may be a post-selection event, involving unique cell
types and/or cytokines in the medulla.
Kinetics and localization of FoxP3+ cells in neonatal thymus organs Figure 4
Kinetics and localization of FoxP3+ cells in neonatal thymus organs. A: FoxP3 expression in 1–6 day old newborn or 
adult thymus lobes was analyzed by immunohistochemical staining with an anti-FoxP3 antibody. Rabbit IgG was used as control. 
No FoxP3+ cells could be detected in the 1–2 day old newborn thymus. In the 3–6 day old thymus, as in the adult thymus, the 
majority of FoxP3+ cells were found in the medullary region. NB: newborn, C: Cortex, M: Medulla. B: Total FoxP3+ cell num-
bers from each section were determined by counting 3 different medulla regions/sections and summarized. C: Immunofluores-
cence phenotyping of FoxP3+ cells in the thymus. a and d: Dapi (Blue), FoxP3 (Red) and CD25 (Green). b and e: FoxP3 (Red) 
and CD25 (Green). c and f: FoxP3 (Red) and CD4 (Blue). C: cortex; M: medulla. In d-f: 1 indicates a CD4+CD25+FoxP3- cell; 2, 
a CD4+CD25+FoxP3+ and 3, a CD4+CD25-FoxP3+ cell.
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CD28-mediated signaling is required for the induction of
FoxP3 and natural Treg generation [32]. The CMJ is
enriched with APC that express the B7 ligands which sig-
nal to CD28. Other factors must, therefore, be provided in
the medulla to lead to functional maturation of FoxP3+
Treg thymocytes. It was recently reported that the Hassall's
corpuscles in the human thymic medulla preferentially
express the cytokine TSLP, which promotes maturation of
DC and induces natural Treg generation [33]. The murine
thymus does not have Hassall's corpuscle-like structures
although mouse TSLP is also predominantly expressed by
medullary TECs in the thymus [33]. We report here that
exogenous mouse TSLP can enhance expression of FoxP3
and maturation of natural Treg cells in mouse FTOC, and
TSLP enhances FoxP3 induction in FTOC Figure 5
TSLP enhances FoxP3 induction in FTOC. A: Induction of FoxP3 expression in FTOC with E17 fetal thymus. Total thy-
mocytes were harvested at 2, 4 and 6 days after E17-FTOC and analyzed for relative expression of FoxP3 (FoxP3/18S) by real-
time PCR. SD is derived from duplicate samples and shown as error bars. At least 3 independent experiments were per-
formed. B: Enhancement of FoxP3 expression by exogenous TSLP in FTOC. FTOCs treated with TSLP (100 ng/ml) were har-
vested after 4 days and analyzed as above. Shown are representative data from at least three independent experiments. C: 
Endogenous TSLPR activity is required for induction of FoxP3 expression. FTOCs were treated with control IgG or anti-
TSLPR antibody. FoxP3 expression after 4 days in culture was analyzed by real-time PCR as above. Error bars indicate standard 
errors from duplicate samples. * indicates p < 0.05. D: FACS analysis of FoxP3 expression in thymocytes from FTOC stimu-
lated with exogenous TSLP. FTOC treated with TSLP was harvested at 4 days post FTOC as above. CD4+CD8- thymocytes 
were gated for analysis of CD4 vs. CD25 and CD25 vs. FoxP3 or isotype control. Shown are representative data from three 
independent experiments.
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that blocking TSLPR leads to reduced expression of FoxP3.
We have detected TSLP gene expression by RT-PCR in 1–6
days old neonatal and adult thymus organs, but its expres-
sion kinetics is not correlated with functional FoxP3+ Treg
development (data not shown). Additional paracrine fac-
tors are probably involved.
How does TSLP modulate maturation of
CD4+CD25+FoxP3+ Treg cells in the thymus? Although
TSLP is expressed predominantly by thymic medullary
stromal cells, its effect on T cells in mice has not been
clearly established [34-36]. In transgenic mice over-
expressing TSLP, development of B cells and T cells
appears to be impaired, but myeloid cell numbers are
increased [37]. In human studies, TSLP has been shown to
modulate DC maturation to indirectly regulate T cell
responses [26-28]. In contrast, mouse TSLP has been
implicated in directly promoting TCR-mediated prolifera-
tion of mouse CD4+ T lymphocytes both from the thymus
and spleen [29]. Our study with purified CD4+ thymo-
TSLP interacts with thymocytes to affect FoxP3 expression and Treg maturation Figure 6
TSLP interacts with thymocytes to affect FoxP3 expression and Treg maturation. Thymocytes from day 2 new-
born mice were cultured with or without TSLP in mFTOC medium for 2 days. Cells were harvested and analyzed by FACS and 
real-time PCR. A and B: TSLP increased maturation of SP, CD4+CD25+ thymocytes and FoxP3 expression. Shown are data 
repeated in at least three independent experiments. C: Absolute numbers of CD4+CD8-, CD4+CD8-CD25+ and 
FoxP3+CD4+CD8-CD25+ in cultures started with initial 10 × 106 total thymocytes from day 2 neonatal mice. Data show mean 
and standard deviation from three different experiments. * indicates p < 0.05 by student's t test. D: TSLP induced FoxP3 
expression in thymocytes from day 2 neonatal mice. Thymocytes were cultured with or without TSLP for 2 days and analyzed 
by real-time PCR as above. * indicates p < 0.05.
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cytes after two days in culture, in the absence of TCR stim-
ulation, suggests that TSLP induces FoxP3 in CD4+CD8-
(both CD25+  and CD25-) thymocytes, but not in
CD4+CD8+ DP or CD4-CD8+ SP8 thymocytes. In addition,
TSLP failed to induce FoxP3 expression in CD4+CD25- T
cells from the spleen under similar culture conditions
(Fig. 10). We also showed that TSLP treatment affected
neither the proliferation nor the survival of CD4+CD25- or
CD4+CD25+ thymocytes during the two day culture in
vitro (Fig. 9). Therefore, TSLP may have a unique effect on
CD4+ thymocytes to induce FoxP3 gene expression that is
distinct from its activity in promoting CD4+ T cell prolif-
eration.
The receptor for TSLP consists of a heterodimer of the
interleukin 7 receptor alpha (IL-7Rα) chain and the TSLP
receptor (TSLPR) that resembles the cytokine receptor
common gamma chain [35,38,39]. As suggested in previ-
ous reports with TSLPR mutant mice [29,36], TSLPR and
other receptors/ligands functionally interact to modulate
B cell development and T cell proliferation. TSLP-medi-
ated signaling is unique among members of the cytokine
receptor family in that activation of the transcription fac-
tor Stat5 occurs without detectable Janus kinase activation
[40,41]. Interestingly, murine TSLPR mediates signals that
are distinct from the Jak3 mediated signals seen with the
common gamma chain [36]. This potentially unique
cytokine signaling activity of TSLPR may be involved in
modulating FoxP3 expression and CD4+CD25+ Treg mat-
uration in thymocytes. TSLP also appears to have different
effects on pro-B cells of fetal and adult origin [42], sug-
gesting distinct signaling networks in developing vs.
TSLP specifically enhances FoxP3 expression in CD4+CD8- thymocytes Figure 7
TSLP specifically enhances FoxP3 expression in CD4+CD8- thymocytes. A: TSLP induced expression of FoxP3 in SP4, 
but not DP, DN and SP8 thymocytes. Purified adult thymocyte subsets were cultured with TSLP and analyzed for FoxP3 
expression by RT-PCR. Relative expression of FoxP3 is shown.B: TSLP induced expression of FoxP3 in both CD4+CD8-CD25- 
and CD4+CD8-CD25+ SP4 thymocytes. Purified thymocytes were cultured and analyzed as above. No FoxP3 gene expression 
is detectable with or without TSLP in CD4-CD8+CD25+ or CD4-CD8+CD25- SP8 thymocytes.
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mature cell types may determine their responsiveness to
TSLP. A similar distinction may exist in the thymocytes
versus peripheral mature T cells as, unlike what we have
seen in the thymus, treatment of CD4+CD25- T cells from
the spleen with TSLP showed no effect on FoxP3 gene
expression (Fig. 10).
Blocking TSLPR in FTOC only partially reduces the
number of FoxP3+CD4+CD25+ thymocytes. In addition,
the frequency and function of FoxP3+CD4+CD25+ Tregs in
the spleen and lymph nodes of TSLPR-null adult mice are
not significantly altered (Q. Jiang, G. Knudsen and L. Su,
unpublished results). Thus, TSLP is involved in, but not
absolutely required, for the process that regulates FoxP3
expression and Treg maturation. Other factors may com-
pensate for the loss of TSLP signaling during embryogen-
esis or during Treg maturation. Paracrine factors known to
be involved in Treg generation and function, including
interleukin-10 and TGFβ, are also expressed in the thymus
and may contribute to this process. For example, TGFβ has
been reported to induce Treg and FoxP3 expression in
mature CD4+CD25-  T cells [11,43]. Our preliminary
results, however, indicate that TGFβ and IL-10 had very
low or no effect on FoxP3 expression in the FTOC model
(Q. Jiang and L. Su, unpublished results). It was recently
reported that the cytokine common gamma chain γc is
required for the expression of FoxP3 and Treg maturation
[44]. In this context, the TSLPR and γc receptor may medi-
ate similar down-stream signals such as STAT5 to activate
FoxP3 gene expression and Treg maturation. It will be of
interest to use STAT5a/b double KO mice [45,46] to test
weather STAT5 is required for the expression of FoxP3 and
Treg generation.
Regulatory CD4+CD25+ T cells have been implicated in a
number of pathologic processes including elevated levels
of Treg cells in certain types of cancer [47-49] and infec-
tious diseases [17,50-52], and reduced Treg levels in
autoimmune diseases [9,53-56]. Novel therapies based on
modulating Treg activity have great potential in treatment
of these diseases and in promoting engraftment of alloge-
neic organ transplant. Elucidating how FoxP3 expression
is modulated during the development of natural Treg cells
in the thymus will be of great importance both for under-
standing the ontogenic mechanism of their development,
and for shedding light on how to modulate their genera-
tion and expansion for use in therapeutic applications.
Methods
Mice, FoxP3 antiserum production and FACS analysis
B6/Ly5.1 and B6/Ly5.2 mice were purchased from the
Jackson Laboratory and TSLP-R-deficient mice were pro-
vided by Dr. J. Ihle in St. Jude Children's Research Hospi-
tal in Tennessee. Scurfy mice (mutation of FoxP3 (FoxP3sf)
genes) were kindly provided by Dr. VL. Godfrey at the
University of North Carolina at Chapel Hill. All mice were
housed at the University of North Carolina at Chapel Hill
as described [57]. The peptide from the N-terminus of
murine FoxP3 (C-LLGTRGSGGPFQGRDLRSGAH) was
chosen to immunize rabbits for production of antibodies.
Affinity purification of the antibodies was done with a
SulfoLink Kit (Pierce Biotechology, Rockford, IL). Mono-
clonal antibodies to CD3, CD4, CD8α and CD25 (Caltag
Laboratories, Burlingame, CA), Annexin V-APC (BD Bio-
sciences, Mountain View, CA) were used for staining and
the affinity purified FoxP3 antibody for intracellular stain-
ing. For proliferation analysis, total thymocytes from
adult mice were labeled with CFSE (1.25 µM) in HBSS/5
% FBS, cells were washed twice, then cultured with or
without TSLP (100 ng/ml) for 2 days before FACS analy-
sis. Cells were analyzed on a FACSCalibur™ flow cytome-
ter (BD Biosciences) as descried [58].
Transfection
The PG-mFoxp3 plasmid was constructed by PCR of
mFoxp3 into the pHSPG vector [57]. 293T cells were
transfected with either empty vector or PG-mFoxp3 using
Effectene Transfection Reagent (Qiagen, Valencia, CA).
Western blot
293T cells transfected with either empty vector or pHSPG-
mFoxp3 were lysed and resolved on a 10% SDS-PAGE.
Gels were transferred to PVDF membranes (Amersham
Pharmacia, NJ), and probed with either control, followed
with the anti-rabbit-IgG-HRP and visualized using an ECL
Kit (Amersham Pharmacia).
TSLP receptor (TSLPR) is required for the enhancement of  FoxP3 expression by TSLP Figure 8
TSLP receptor (TSLPR) is required for the enhance-
ment of FoxP3 expression by TSLP. Thymocytes from 
wild type or TSLPR-null mice (4–6 weeks of age) were cul-
tured with or without TSLP (100 ng/ml) for 2 days and ana-
lyzed for relative expression of FoxP3 (FoxP3/18S) by real-
time PCR. Error bars indicate SD derived from duplicate 
samples. Shown are data repeated in at least three independ-
ent experiments.
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TSLP does not affect the proliferation and survival of CD4+CD25- or CD4+CD25+ thymocytes in vitro Figure 9
TSLP does not affect the proliferation and survival of CD4+CD25- or CD4+CD25+ thymocytes in vitro. A. Lack of 
proliferation of thymocytes in the absence or presence of TSLP. Total thymocytes from 4–6 weeks old mice were pre-labeled 
with CSFE, and then cultured with or without TSLP (100 ng/ml) for two days. Thymocytes were analyzed for CD4, CD8, 
CD25 and CFSE by FACS. Relative CFSE levels on CD25- and CD25+ SP thymocytes (CD4+ SP and CD8+ SP) were measured. 
No significant proliferation was detected in these thymocytes under the culture conditions. B. TSLP does not affect apoptosis 
of thymocytes. Total adult thymocytes were cultured with or without TSLP for 2 days. Annexin V+ cells in the CD4+CD25- and 
CD4+CD25+ populations are shown by FACS analysis. Similar results were obtained in three independent experiments.
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Real-time PCR
RNA and cDNA were prepared with the cells to cDNA kit
(Ambion, Inc, Austin, Texas). mRNA levels of FoxP3 and
18S were measured by TaqMan real-time PCR using the
primers and ABI 7000 Sequence Detection System
(Applied Biosystems Inc.). FoxP3 mRNA levels were nor-
malized relative to 18S. All samples were run in duplicates
and repeated in at least three independent experiments.
Immunostaining
For immunohistochemical staining, paraffin-embedded
sections of thymus organs from new born or adult mice
were stained with the anti-FoxP3 antibody, goat anti-rab-
bit biotin and the Avidin-Biotin Complex (ABC) (Vector,
CA) and substrate DAB (Pierce, IL). For immunoflures-
cence staining of 293T cells, after transfection with an vec-
tor expressing both FoxP3 and GFP on coverslips, cells
were stained with pre-immune serum or anti-Foxp3
serum, followed by Rhodamine (TRITC)-conjugated goat
anti-rabbit IgG (H+L) (Jackson ImmunoReasearch Labo-
ratories, INC PA). For immunoflurescence staining of thy-
mus organs, frozen sections were incubated with the anti-
FoxP3 antibody followed by goat anti-rabbit IgG-Alexa
Fluor 546 (Molecular Probes, CA), mouse CD25-Alexa
Fluor 488 and mouse CD4-Alexa Fluor 647 (Caltag, CA).
Nuclei were counterstained with DAPI. The sections were
examined with a LeicaSP2 confocal microscope (Leica,
Bannockburn, IL).
E17 FTOC assays
Thymic lobes from day 17 embryos were cultured on the
membranes at an interface between 5 % CO2-humidified
air and mFTOC media (RPMI 1640 (BRL), 10 % fetal
bovine serum, 50 µM 2-mercaptoethanol, 2 mM L-
glutamine, 1 % nonessential amino acid (Life Technolo-
gies, Gaithersburg, MD), 10 mM HEPES, 1 mM sodium
pyruvate solution (GIBCO BRL), 100 U/ml Penicillin and
100 mg/ml Streptomycin). In E17 thymus organ culture
system, lobes were cultured with or without recombinant
mouse TSLP (R&D Systems, Minneapolis, MN) or mono-
clonal rat anti-mouse TSLPR antibody (R&D Systems).
Cells from thymic lobes were harvested at different days
and analyzed by flow cytometer or real-time PCR.
Newborn, adult thymocytes or adult splenocytes culture in 
vitro
Thymocytes from day 2 newborn mice or 2–3 month old
adult mice were harvested. Different subpopulations of
adult thymocytes and splenocytes were sorted on a Cyto-
mation MoFlo FACS. Cells were cultured in FTOC media
with or without recombinant mouse TSLP (R&D Sys-
tems). Two days later, cells were isolated and analyzed by
PCR or on a FACSCalibur™ flow cytometer.
Treg proliferation and suppression assay
Thymus organs from day 2 newborn or adult mice and
spleens from adult mice were harvested. To isolate Treg
cells from thymocytes, cells were stained with anti-CD4,
anti-CD8 and anti-CD25 antibodies, CD4+CD8-CD25+
and CD4+CD8-CD25- cells were sorted on a Cytomation
MoFlo machine. CD90- APCs were purified on the autoM-
ACS system using CD90 microbeads (Miltenyi Biotec,
Auburn). The proliferation and suppression assay of Treg
cells was performed as described [59]. Purified day 2 new-
born CD4+CD8-CD25+, CD4+CD8-CD25-  cells (7.5 ×
103), or adult CD4+CD25+ (7.5 × 103) Treg are cocultured
with CD4+25- cells (1.5 × 104) and irradiated (2100 rad)
CD90-depleted splenocytes (1.5 × 104) as APCs in the
presence of ConA (5 µg/ml). Cells were cocultured for 3
days, and pulsed with 1 µCi 3H-thymidine 6 h before har-
vesting.
Abbreviations
Treg: regulatory T cells;
FTOC: fetal thymus organ culture;
TSLP: thymus stromal-derived lymphopoietin;
mTEC: medullary thymic epithelial cells.
CMJ: cortical-medullary junctions.
APC: antigen presenting cells.
TSLP does not induce Foxp3 expression in CD4+25- spleen T  cells Figure 10
TSLP does not induce Foxp3 expression in CD4+25- 
spleen T cells. CD4+25- T cells purified from the spleen 
were cultured with or without TSLP (100 ng/ml) for 2 days 
and analyzed for relative expression of FoxP3 (FoxP3/18S) by 
real-time PCR. Error bars indicate SD derived from duplicate 
samples. Shown are data repeated in at least three independ-
ent experiments.
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